Development and Commercialization Licenses Sample Clauses
The Development and Commercialization Licenses clause grants one party the legal rights to develop, manufacture, and sell products or technologies covered by the agreement. Typically, this clause outlines the scope of the license, such as whether it is exclusive or non-exclusive, the specific territories or fields of use, and any obligations regarding milestones or performance. Its core function is to clearly allocate rights and responsibilities for bringing a product to market, ensuring both parties understand their roles and reducing the risk of future disputes over intellectual property use.
Development and Commercialization Licenses. Subject to the terms and conditions of this Agreement, Bayer agrees to grant and hereby grants to Licensee, together with the right to grant sublicenses, subject to Section 2.2:
2.1.1.1 an exclusive (except as otherwise provided in Section 2.5 below), worldwide license under the Bayer Intellectual Property to Develop (except for CMC/Process Development) the Product in the Territory for use in the Field; and
2.1.1.2 an exclusive (except as otherwise provided in Section 2.5 below), worldwide, royalty-bearing license under the Bayer Intellectual Property to Commercialize the Product in the Territory for use in the Field.
Development and Commercialization Licenses. Subject to Section 4.3.4 (Sublicense and License Requirements), NVS may sublicense its rights under Section 4.1.2 (Development and Commercialization License) without HMI’s prior written consent (a) to any Third Party service provider performing services for the benefit of NVS in connection with the Development or Commercialization of any Candidate or Product, or (b) to any Third Party to whom NVS desires to sublicense Development or Commercialization rights in any and all jurisdictions; provided, [***].
Development and Commercialization Licenses. Subject to the terms and conditions of this Agreement, commencing upon the designation of a
Development and Commercialization Licenses. Subject to the terms and conditions of this Agreement, on a Collaboration Target-by-Collaboration Target basis, effective upon Vertex’s exercise of the Option for a particular Collaboration Target in accordance with this Agreement, CRISPR and, following the Subsidiary Transfer, the CRISPR Subsidiary, grants to Vertex UK and its Affiliates an exclusive (subject to Section 6.1.2(b)), royalty-bearing, license under CRISPR’s and its Affiliates’ interest in the Licensed Technology to Research, Develop, Manufacture, have Manufactured, use, keep, sell, offer for sale, import, export and Commercialize Licensed Agents and Products directed to the relevant Collaboration Target in the Field in the Territory (such license, the “Exclusive License”). Vertex may grant sublicenses through multiple tiers of sublicense to one or more Sublicensees of any and all rights granted to Vertex by CRISPR under the Exclusive License; provided that Vertex shall only be permitted to grant a Sublicense to conduct any Commercialization activities with respect to a Licensed Agent or Product [***] with CRISPR’s prior written consent, such consent not to be unreasonably withheld, conditioned or delayed; and provided, further, that no such consent will be needed with respect to any Sublicense (a) granted to a Third Party to conduct Commercialization activities with respect to a Licensed Agent or Product in [***] (and not any other [***]), (b) any Sublicense granted to a Distributor or other Third Party conducting activities on Vertex’s behalf or (c) any Sublicensee granted to a Third Party to Manufacture Licensed Agent or Product on [***] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 406 of the Securities Act of 1933, as amended.
1). Notwithstanding the grant of any Sublicense, Vertex shall remain primarily liable to CRISPR for the performance of all of Vertex’s obligations under, and Vertex’s compliance with all provisions of, this Agreement.
Development and Commercialization Licenses. Subject to the terms and conditions of this Agreement, Vertex grants to CRISPR a co-exclusive (with Vertex and its Affiliates) license under Vertex’s and its Affiliates’ interest in the Licensed Vertex Technology, with the right to Sublicense through multiple tiers (subject to Section 10.5), to Research, Develop, Manufacture, have Manufactured, use, keep, sell, offer for sale, import, export and Commercialize Shared Products in the Field in the Territory.
Development and Commercialization Licenses. Subject to the terms and conditions of this Agreement, CRISPR and, following the Subsidiary Transfer, the CRISPR Subsidiary, grants to Vertex UK and its Affiliates a co-exclusive (with CRISPR) license under CRISPR’s and its Affiliates’ interest in the Licensed CRISPR Technology, with the right to Sublicense through multiple tiers (subject to Section 10.5), to Research, Develop, Manufacture, have Manufactured, use, keep, sell, offer for sale, import, export and Commercialize Shared Products in the Field in the Territory (such license, the “Exclusive License”). As of the Effective Date, this Exclusive License supersedes and replaces the license grant set forth in Section 5.3.1 of the Collaboration Agreement solely with respect to the Shared Targets, and shall be deemed to be the “Exclusive License” under the Collaboration Agreement with respect to the Shared Targets. [***] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. Table of Contents
Development and Commercialization Licenses. Subject to the terms and conditions of this Agreement, commencing upon the designation of a Claimed Target as a Committed Lead Target pursuant to Section 3.4.4, FivePrime hereby grants to GSK an exclusive, royalty-bearing license (as set forth in Article 6), with the right to grant sublicenses (including the right to further sublicense) pursuant to Section 4.1.3, under the FivePrime Collaboration Patent Rights, FivePrime Collaboration Know-How, and FivePrime’s interest in the Joint Patent Rights and Joint Know-How, to make, have made, use, sell, offer for sale and import Licensed Product(s) (for any ***, solely in the ***) with respect to such Committed Lead Target in the Field in the Territory, and a non-exclusive, royalty-free license, with the right to grant sublicenses (including the right to further sublicense) pursuant to Section 4.1.3, under the FivePrime Background Know-How and FivePrime Background Patents, solely to the extent necessary to exercise the exclusive license granted in this Section 4.1.2
Development and Commercialization Licenses. Subject to the terms and conditions of this Agreement, on a Collaboration Program-by-Collaboration Program basis, effective upon the License Effective Date for a particular Collaboration Program in accordance with this Agreement, Ionis grants to Biogen a worldwide, exclusive, royalty-bearing, sublicensable (in accordance with Section 4.1.2 below) license under the Licensed Technology to research, Develop, Manufacture, have Manufactured (in accordance with Section 4.1.2 below), register, market and Commercialize Products under such Collaboration Program in the Field.
Development and Commercialization Licenses. (a) Subject to the terms and conditions of this Agreement [**], ▇▇▇▇▇▇ hereby grants to Millennium a worldwide, co-exclusive (with ▇▇▇▇▇▇) license, under ▇▇▇▇▇▇'▇ rights to the Program Intellectual Property, to (i) Develop and Manufacture Joint DDCs for use as Joint Products; (ii) make, have made (subject, in the case of any sublicense, to the provisions of Section 8.3), use, sell, offer for sale, import and export Joint Products in the Territory; and (iii) undertake such other activities as may be necessary in furtherance of the Development Program and the Commercialization Program. Such license shall carry an obligation of profit-sharing Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions. with respect to Joint Products sold in the Territory, as set forth in Section 9.1. Such license shall further include the right to grant sublicenses to Affiliates of Millennium and to Third Parties in accordance with the terms set forth in Section 8.3. For purposes of clarity, ▇▇▇▇▇▇'▇ co-exclusive right retained under this Section 8.2.2(a) includes the right to grant sublicenses to Affiliates of ▇▇▇▇▇▇ and to Third Parties in accordance with the terms set forth in Section 8.3.
(b) Subject to the terms and conditions of this Agreement (including, but not limited to, the exclusivity provisions of Section 2.1.
Development and Commercialization Licenses. Subject to the terms and conditions of this Agreement, on a Collaboration Target-by-Collaboration Target basis, effective upon Vertex’s exercise of the Option for a particular Collaboration Target in accordance with this Agreement, CRISPR and, following the Subsidiary Transfer, the CRISPR Subsidiary, grants to Vertex UK and its Affiliates an exclusive (subject to Section 6.1.2(b)), royalty-bearing, license under CRISPR’s and its Affiliates’ interest in the Licensed Technology